ATE509092T1 - Rekombinante bcg-stämme mit verbesserter fähigkeit zum entweichen aus dem endosom - Google Patents

Rekombinante bcg-stämme mit verbesserter fähigkeit zum entweichen aus dem endosom

Info

Publication number
ATE509092T1
ATE509092T1 AT05858631T AT05858631T ATE509092T1 AT E509092 T1 ATE509092 T1 AT E509092T1 AT 05858631 T AT05858631 T AT 05858631T AT 05858631 T AT05858631 T AT 05858631T AT E509092 T1 ATE509092 T1 AT E509092T1
Authority
AT
Austria
Prior art keywords
endosome
escape
improved ability
recombinant bcg
bcg strains
Prior art date
Application number
AT05858631T
Other languages
English (en)
Inventor
Ronggai Sun
David Hone
Jerald Sadoff
Original Assignee
Aeras Global Tb Vaccine Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeras Global Tb Vaccine Foundation filed Critical Aeras Global Tb Vaccine Foundation
Application granted granted Critical
Publication of ATE509092T1 publication Critical patent/ATE509092T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05858631T 2004-12-01 2005-11-23 Rekombinante bcg-stämme mit verbesserter fähigkeit zum entweichen aus dem endosom ATE509092T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63197304P 2004-12-01 2004-12-01
PCT/US2005/042602 WO2007058663A2 (en) 2004-12-01 2005-11-23 Recombinant bcg strains with enhanced ability to escape the endosome

Publications (1)

Publication Number Publication Date
ATE509092T1 true ATE509092T1 (de) 2011-05-15

Family

ID=38049094

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05858631T ATE509092T1 (de) 2004-12-01 2005-11-23 Rekombinante bcg-stämme mit verbesserter fähigkeit zum entweichen aus dem endosom

Country Status (17)

Country Link
US (3) US20100047286A1 (de)
EP (1) EP1827504B1 (de)
JP (1) JP5713523B2 (de)
KR (1) KR101329323B1 (de)
CN (1) CN101198358B (de)
AP (1) AP2007004033A0 (de)
AT (1) ATE509092T1 (de)
AU (1) AU2005338353B2 (de)
BR (1) BRPI0518091A2 (de)
CA (1) CA2589204C (de)
DK (1) DK1827504T3 (de)
EA (1) EA012434B1 (de)
ES (1) ES2366622T3 (de)
PE (1) PE20061168A1 (de)
TW (1) TWI456057B (de)
WO (1) WO2007058663A2 (de)
ZA (1) ZA200704765B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
BRPI0518933A2 (pt) * 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
US8501190B2 (en) * 2007-06-22 2013-08-06 The University Of Guelph Vaccine against Clostridium perfringens
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
KR101928684B1 (ko) * 2009-01-08 2018-12-12 앨버트 아인슈타인 컬리지 오브 메디신, 인크. 세포벽 결합 세라미드 유사 당지질을 갖는 박테리아 백신 및 이의 용도
EP2694667B1 (de) * 2011-04-08 2016-12-07 Baystate Medical Center, Inc. Verfahren, zusammensetzungen und kits zum testen der mitochondrienfunktion
US20130115240A1 (en) * 2011-11-09 2013-05-09 National Health Research Institutes Recombinant bcg strains with enhanced ability to inhibit intracellular mycobacterial growth
WO2013151731A1 (en) * 2012-04-02 2013-10-10 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
WO2013158061A1 (en) 2012-04-16 2013-10-24 Aeras Global Tb Vaccine Foundation Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof
GB2521573A (en) * 2012-09-27 2015-06-24 Chengdu Yongan Pharmaceutical Co; Ltd Modified BCG strains with reduced or eliminated activity of LSR2 and pharmaceutical composition comprising same
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
EP3013364B1 (de) 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberkulosezusammensetzungen und verfahren zur verwendung davon
US10428122B2 (en) 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
AU2017280065B2 (en) 2016-06-22 2021-07-01 International Aids Vaccine Initiative, Inc. Recombinant cytomegalovirus vectors as vaccines for tuberculosis
WO2019079155A1 (en) 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. CASSETTES OF ANTIGENS OF TUBERCULOSIS
KR102260116B1 (ko) 2018-11-19 2021-06-04 중앙대학교 산학협력단 항균 펩타이드 회피 유전자를 포함하는 재조합 바실러스 칼메트-게렝균의 방광암 항암 치료용 약학적 조성물
KR20200058319A (ko) 2018-11-19 2020-05-27 중앙대학교 산학협력단 항균 펩타이드 회피 유전자를 포함하는 재조합 바실러스 칼메트-게렝균의 방광암 항암 치료용 약학적 조성물
KR102135328B1 (ko) * 2018-12-19 2020-07-17 대한민국 결핵 2가 항원을 발현하는 약독화된 재조합 백시니아 바이러스 및 이를 포함하는 결핵 예방용 조성물
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN114438106B (zh) * 2022-02-14 2024-01-19 首都医科大学附属北京胸科医院 Rv2779c基因及其表达产物作为抗结核分枝杆菌靶点的应用
WO2025179079A1 (en) * 2024-02-21 2025-08-28 The Regents Of The University Of Colorado A Body Corporate Use of mycobacterium to prevent, treat, or reduce adiposity and diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731151A (en) * 1993-05-24 1998-03-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Regulator of contact-mediated hemolysin
EP0902086A1 (de) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberkolose Impfstoff
US6423545B1 (en) * 1999-07-08 2002-07-23 Albert Einstein College Of Medicine Of Yeshiva University Unmarked deletion mutants of mycobacteria and methods of using same
US6776993B2 (en) 2000-02-22 2004-08-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US6924118B2 (en) * 2000-04-17 2005-08-02 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
US6471967B1 (en) * 2000-04-17 2002-10-29 The Regents Of The University Of California Recombinant intracellular pathogen vaccines and methods for use
DK1618128T3 (da) 2003-04-23 2010-10-18 Max Planck Gesellschaft Tuberkulosevaccine med forbedret effektivitet
EP1649869A1 (de) 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Kombination von rekombinanten Mycobakterien und einem biologisch aktiven Agent als Vakzine
CA2587507C (en) * 2004-12-01 2013-11-19 Aeras Global Tb Vaccine Foundation Electroporation of mycobacterium and overexpression of antigens in mycobacteria

Also Published As

Publication number Publication date
TWI456057B (zh) 2014-10-11
DK1827504T3 (da) 2011-08-29
BRPI0518091A2 (pt) 2008-11-25
JP2008521449A (ja) 2008-06-26
CN101198358A (zh) 2008-06-11
TW200637910A (en) 2006-11-01
CA2589204C (en) 2013-10-29
EP1827504A4 (de) 2008-11-12
EP1827504A2 (de) 2007-09-05
KR101329323B1 (ko) 2013-11-14
PE20061168A1 (es) 2006-10-27
ZA200704765B (en) 2008-09-25
US7666656B2 (en) 2010-02-23
AU2005338353B2 (en) 2011-04-14
US8043857B2 (en) 2011-10-25
CN101198358B (zh) 2013-06-26
US20100233213A1 (en) 2010-09-16
US20080095794A1 (en) 2008-04-24
AP2007004033A0 (en) 2007-06-30
KR20070101855A (ko) 2007-10-17
CA2589204A1 (en) 2007-05-24
AU2005338353A1 (en) 2007-05-24
ES2366622T3 (es) 2011-10-24
WO2007058663A3 (en) 2007-07-12
EA012434B1 (ru) 2009-10-30
EP1827504B1 (de) 2011-05-11
EA200701128A1 (ru) 2008-02-28
WO2007058663A2 (en) 2007-05-24
US20100047286A1 (en) 2010-02-25
JP5713523B2 (ja) 2015-05-07

Similar Documents

Publication Publication Date Title
DK1827504T3 (da) Rekombinante BCG-stammer med forøget evne til at undslippe fra endosomet
ITTO20050525A1 (it) Lembi perfezionati per ridurre gli effetti dannosi dei detriti.
IL211762A0 (en) Pegylated opiods, compositions comprising the same and uses thereof
ES2401092T8 (es) Material compuesto elástico transpirable
DK2035447T3 (da) Polypeptid
DK3144318T3 (da) Rekombinant fsh, der omfatter alpha 2,3- og alpha 2,6-sialylering
PL2470517T3 (pl) Estry kwasu 2,5-furanodikarboksylowego z izometrycznymi dekanolami i ich zastosowanie
DK2205562T3 (da) 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
EP2249411A4 (de) Schichtstruktur
BRPI0811116A2 (pt) Material protetor.
IL211400A0 (en) Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
DE602006004024D1 (de) Handschuhe mit erhöhter stulpenrutschfester oberfläche
ATE475706T1 (de) Abgeschwächter dengue-serotyp-2-stamm
IL207648A0 (en) Polypeptide having glyoxalase iii activity, polynucleotied encoding the same and uses thereof
EP2295389A4 (de) Piezoelektrische keramikzusammensetzung und piezoelektrisches element daraus
DE602005015286D1 (de) Atmungsfähige, wasserdichte laminatstruktur
PT1925747T (pt) Elemento para a formação de quebra-mares
IT1393655B1 (it) Composizione pesticida
FI20080124A0 (fi) Läheis-Josephson-ilmaisin
DE602005003074D1 (de) Fluorocopolymer
IT1393650B1 (it) Composizione pesticida
ITMI20081572A1 (it) Composizione pesticida
EP2195338A4 (de) N-terminal modifiziertes interferon-alpha
IL205843A0 (en) Novel immunoregulatory peptides, compositions and uses thereof
IT1394286B1 (it) " fucile mitragliatore tipo "thompson mod. 1928 a 1 e 1927 ".

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties